Seeking Alpha
06 Aug 2026, 05:41 UTC · 1h ago
Pacific Biosciences: It's Only Getting Worse
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Seeking Alpha
06 Aug 2026, 05:41 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Pacific Biosciences lowered its 2026 revenue guidance to levels below market consensus. — Downwards revisions to long-term growth targets typically trigger significant valuation resets in growth-oriented biotech stocks.
-0.80The company reported Q2 revenues of $39.01 million, missing analyst estimates. — Immediate revenue misses signal current operational struggles and lack of short-term momentum.
-0.50The company maintains a precarious balance sheet with under $237 million in cash against $645 million in outstanding debt. — A high debt-to-cash ratio increases insolvency risk and limits the company's ability to fund operations without further dilution or borrowing.
-0.40Which stocks this story touches
Continue reading
6 related stories
Top 2 movers · tap to explore
The company missed revenue estimates, lowered future guidance, and reports significant losses and debt.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Seeking Alpha
1h ago
